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INTERMITTENT VERSUS CONTINUOUS CHEMOTHERAPY FOR FIRST-LINE
TREATMENT OF UNRESECTABLE METASTATIC COLORECTAL CANCER (CCRM):
SYSTEMATIC REVIEW AND META-ANALYSIS
Botrel TEA1, Paladini L2, Clark O1, Clark LGO1
1Evidências, Campinas, Brazil, 2Evidências, São Paulo, São Paulo, Brazil
OBJECTIVES: To perform a systematic review and meta-analysis of all randomized
controlled trials comparing efficacy of Intermittent versus continuous chemother-
apy (CT) for first-line treatment of unresectable Metastatic Colorectal Cancer
(CCRm). METHODS: Several databases were searched, including MEDLINE, EM-
BASE, LILACS, and CENTRAL. The primary endpoint was overall survival (OS). The
data extracted from the studies were combined by using Hazard Ratio (HR) with
their corresponding 95% confidence intervals (CI95%). RESULTS: Overall, 733 refer-
ences were identified and screened. The final analysis included 4 trials comprising
1,827 patients analyzed. There was no statistically significant difference between
the groups (Intermittent vs continuous chemotherapy) on the analysis of overall
survival (fixed effect: HR1.03, CI95%0.92 to 1.16; p0.56). No heterogeneity was
detected on this analysis (Chi2  2.88, df  3 (P0.41); I2  0%). CONCLUSIONS:
Overall survival was similar between groups. The intermittent chemotherapy reg-
imen provides better quality of life that the scheme is continued and probably cost
saving.
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THE BROADER BURDEN OF HPV-RELATED DISEASE IN ENGLAND: A
PRELIMINARY ANALYSIS
Khalid JM1, Amelio JM1, Carroll SM2, Charman F2, Maguire A1
1United Biosource Corporation, London, UK, 2Sanofi Pasteur MSD, Maidenhead, UK
OBJECTIVES: The Human Papillomavirus (HPV) is a known cause of cervical cancer
and genital warts, and causes a proportion of vaginal, vulval, penile, anal, and head
and neck (HN) cancers. Quantifying the broader burden of HPV-related cancers is
important as this group represents approximately 5.2% of all cancers. METHODS:
Using cancer registry data covering the population of England (2003-2008), we ex-
amined incidence of HPV-related cancers. HPV-associated sites were identified
(cervix, vulva, vagina, anus, penis and HN) and grouped according to ICD-O-3 site.
Incidence rates were age-adjusted (ASR) to the European standard population by
the direct method and 95% Confidence intervals (95% CI) calculated using STATA
SE11.0. A literature review was conducted to ascertain the percentage attributable
to HPV for each cancer type. Over 300 articles were reviewed and graded by rele-
vance, sample size, and date.RESULTS:ASRs for HPV-related cancers were: vagina/
vulval cancers: 0.33(95% CI 0.3-0.4) and 1.4(95% CI: 1.3-1.4) per 100,000 females.
Penile cancer: 0.8(95% CI: 0.7-0.8) per 100,000 males. Anal cancers: 10.8(95% CI:10.7-
11.1) males and 6.0(95% CI:5.8-6.0) females per 100,000. Base of tongue and lingual
tonsil: 0.06(95% CI:0.06-0.07) males and 0.02(95% CI:0.01-0.02) females per 100,000;
tonsil: 0.11(95% CI:0.10-0.12) males and 0.03(95% CI:0.03-0.04) females per 100,000;
oropharynx: 0.05(95% CI:0.05-0.06) males and 0.02(95% CI:0.01-0.02) females per
100,000. Estimates reported in literature for percentage of HPV-attributable cases
ranged from 70-100% for cervical, 27-76% vulval, 70-90% vaginal, 40-54% penile,
76-90% anal, and 11-72% for HPV-associated HN cancers. The most commonly
reported strains were HPV 16, 18, 31, and 33. CONCLUSIONS: The incidence of
HPV-related cancers represents a significant burden. Recent incidence estimates
are similar to 2002 estimates, apart from an increase in anal cancers. Estimates of
the HPV-attributable percentage for each cancer and projected prevalence will be
used to assess the impact of implementing a quadrivalent HPV vaccination pro-
gramme in England.
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SYSTEMATIC REVIEW OF SKELETAL RELATED EVENTS IN BREAST CANCER
Broder M1, Gutierrez B2, Linhares Y1, Cherepanov D1
1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2Bristol-Myers Squibb,
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OBJECTIVES: Metastatic bone lesions lead to an increase in the risk for skeletal
related events (SREs), including pathologic fracture, spinal cord compression, hy-
percalcemia of malignancy, and severe bone pain requiring palliative radiotherapy
or surgery to bone. Twenty-nine percent of breast cancer patients with bone me-
tastases develop SREs. Our objective was to systematically review the literature on
the impact of SREs on pain, quality of life (QOL), morbidity, survival and cost in
breast cancer patients.METHODS:We searched PubMed, limiting to peer-reviewed
English-language human studies published in 2000-2010. The search was based on
a SRE definition accepted by the U.S. Food and Drug Administration and European
Medicines Agency. Articles were included if they were randomized-controlled tri-
als, clinical trials with appropriate control group, systematic reviews, meta-analy-
ses, case-series or economic analyses, and were excluded if they did not provide
interpretable results on outcomes of interest. RESULTS: A total of 209 articles were
screened, of which 131 were excluded, and 78 were abstracted. No studies, outside
of bisphosphonate trials, were identified that examined the impact of SREs as a
group on clinical outcomes. Bisphosphonate treatment reduced SREs, and hence
improved pain and QOL. Literature indicated that presence of pathologic bone
fractures is correlated with increased risk of death. Spinal cord compression sig-
nificantly impaired ambulatory function and shortened survival of these patients
compared to historical controls. Radiation therapy improved pain and QOL while
bone surgery was shown to improve pain and function with vertebrectomy. Lim-
ited evidence suggested treatment cost of SREs is $14,000 (95% CI: $11,000-$17,000)
per patient. CONCLUSIONS: Presence of clinical SREs is associated with worse
morbidity and survival, while their treatment is associated with improved pain,
QOL and morbidity among breast cancer patients. SREs appear to increase cost of
treatment substantially.
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SYSTEMATIC REVIEW OF SKELETAL RELATED EVENTS IN PROSTATE CANCER
Broder M1, Gutierrez B2, Linhares Y1, Cherepanov D1
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OBJECTIVES: Between 65-75% of patients with prostate cancer experience meta-
static bone disease. Metastatic bone lesions increase risk for skeletal related events
(SREs), which include clinical SREs (pathologic fracture, spinal cord compression,
hypercalcemia of malignancy) and treatments of clinical SREs (radiotherapy or
surgery to bone) resulting from severe bone pain. Our objective was to systemati-
cally review the literature on the impact of SREs on pain, quality of life (QOL),
morbidity, survival and cost in prostate cancer patients. METHODS: We searched
PubMed, limiting to peer-reviewed English-language human studies published in
2000-2010. The search was based on SRE definition accepted by the US Food and
Drug Administration and European Medicines Agency. Articles were included if
they were randomized-controlled trials, clinical trials with appropriate control
group, systematic reviews, meta-analyses, case-series or economic analyses, and
were excluded if they did not provide interpretable results on outcomes of interest.
RESULTS:A total of 209 articles were screened, of which 131 were excluded, and 78
were abstracted. No studies, outside of bisphosphonate trials, were identified that
examined the impact of SREs as a group on clinical outcomes. In bisphosphonate
trials, patients with SREs had significantly more pain and worse 1-year survival
compared with no SREs. Pathologic bone fractures significantly decreased QOL and
were associated with increased risk of death. Although spinal cord compression
(SCC) has a significant impact on pain, improvement in morbidity may be achieved
if SCC is treated. SCC is associated with significant decreases in patient survival.
Radiation therapy improved pain and possibly QOL while bone surgery improved
pain. Limited evidence suggested SREs increased cost by approximately €7,000
(Euros) and $12,000 (USD). CONCLUSIONS: Clinical SREs are associated with worse
clinical outcomes, including pain, QOL, morbidity and survival, while treatment of
clinical SREs is associated with improved pain and QOL among prostate cancer
patients. SREs appear to increase cost substantially.
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SAFETY PROFILE OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
Castillo MA, Ubago R, Flores S, Rodríguez R, Beltrán C
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Castillo MA, Ubago R, Flores S, Rodríguez R, Beltrán CAgencia de Evaluación de Tecnologías
Sanitarias de Andalucía, Seville, Andalucia, Spain
OBJECTIVES: To assess the overall risk of bevacizumab related adverse events in
patients with metastatic colorectal cancer (mCRC).METHODS:A systematic review
of the literature was conducted. The selection criteria of the studies for this review
were: health technology agencies reports, meta-analysis, systematic reviews, ran-
domized controlled trials (RCTs) and observational studies in patients treated with
bevacizumab for mCRC. MEDLINE, EMBASE, the Cochrane Library, and CRD data-
bases were searched until June 8, 2011. The selection of the studies, quality assess-
ment, data extraction and data analysis were done independently by two authors.
Disagreements were resolved by a third reviewer until consensus was obtained.
RESULTS: To evaluate the safety profile of bevacizumab, two systematic reviews
with meta-analysis and two observational studies were included (the BEAT and the
BRiTE studies). A total of 3271 patients were included in one meta-analysis, which
evaluated the risk of fatal adverse events (FAE) and 3,385 patients were included in
the other meta-analysis, which evaluated any grade of toxicity. An increased risk of
FAE was not observed between patients with mCRC receiving bevacizumab in com-
bination with chemotherapy and patients receiving chemotherapy alone [Relative
Risk (RR):1.21 Confidence Interval (CI) 95%: 0.65-2.24]. Patients treated with bevaci-
zumab had an increased risk of developing grade 3-4 hypertension (RR: 4.27; CI95%:
2.80–6.51), any grade gastrointestinal perforation (RR: 5.04; CI95%: 1.72–14.79),
grade 3-4 arterial thromboembolic events (RR: 1.23; CI95%: 0.93–1.62), and discon-
tinuation because of grade 3-4 adverse events (RR: 1.21; CI95%: 1.03–1.43). The
results from the observational studies were consistent with the data reported in
the meta-analysis. CONCLUSIONS: Although the risk of FAE was not increased
with bevacizumab in patients with mCRC, grade 3-4 hypertension, any grade gas-
trointestinal perforation, grade 3-4 arterial thromboembolic events, and discontin-
uation due to grade 3-4 adverse events were higher in the bevacizumab group.
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SURVIVAL ANALYSES ADJUSTED FOR CROSSOVER IN RELAPSED MULTIPLE
MYELOMA: RESULTS OF THE APEX TRIAL
Pacou M1, Gauthier A1, Abrams K2, Spencer M3
1Amaris Consulting UK, London, UK, 2University of Leicester, Leicester, UK, 3Janssen-Cilag
Limited, High Wycombe, UK
OBJECTIVES: An interim analysis of APEX, a phase III randomized, open-label clin-
ical trial, demonstrated superiority of bortezomib over high-dose dexamethasone
in terms of time to disease progression (TTP). According to the original study pro-
tocol, patients were allowed to cross over on disease progression. Following in-
terim analysis, patients could cross over regardless of the disease status. The ITT
analysis of overall survival (OS) may therefore result in a biased estimate of the
treatment effect. This study aimed to adjust the analysis for crossover. METHODS:
The Iterative Parameter Estimation (IPE) algorithm using a Weibull distribution was
selected as the primary analysis based on the findings from a simulation study
(Morden et al). The IPE algorithm using a Gompertz distribution and the Rank
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Preserving Survival Time (RPSFT) model were used as secondary analyses. The
Inverse Probability of Censoring Weights (IPCW) method and the Cox model using
treatment as a time-dependent covariate were used as sensitivity analyses.
RESULTS: Overall, 71% of patients randomized to dexamethasone crossed over to
bortezomib. The primary analysis led to a hazard ratio of 0.59 (95%CI: [0.32,0.86]) for
bortezomib versus dexamethasone, compared to 0.77 (95%CI: [0.61,0.97]) using the
ITT approach. The results of the secondary analyses were consistent with the
primary analysis. The IPCW provided results, which were very sensitive to the
choice of the time interval. Lastly, the Cox model with treatment as a time-depen-
dent variable resulted in a counter-intuitive higher hazard ratio than the ITT anal-
ysis, consistent with results from simulation studies indicating this approach is
biased.CONCLUSIONS:Adjusting for crossover led to a decrease of the hazard ratio
from 0.77 to 0.59, and resulted in wider confidence intervals than the ITT analysis.
Additional analyses are required to assess the performance of the IPCW method
compared to the IPE algorithm and the RPSFT model under different scenarios.
Cancer – Cost Studies
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BUDGET IMPACT MODEL FOR RARE CANCER TREATMENT: CASE IN POINT
CUTANEOUS T-CELL LYMPHOMA
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: Develop budget impact model to forecast total cost of treatment for
cutaneous T-cell lymphoma (CTCL) for US public and private payer.METHODS:The
clinical efficacy and safety data were obtained from the published pivotal study
results. Costs of adverse events were estimated based on claims database analysis,
AHRQ’s HCUP and CMS Medicare 2009 databases. Drug cost was estimated based
on 2011 AWP price. Epidemiology data were obtained from NCI-SEER and CDC
databases. A budget impact model was implemented over a period of five years,
based on a stable population and on different penetration and substitution rates of
newly approved therapy. Model was developed in excel based format. Blinded
Model design and outputs were tested with payers and KOLs. RESULTS: For rare
cancers such as CTCL, the budget impact of treatment with targeted cancer therapies
is in the range of $460,000-$530,000 per 1 million covered lives. The per patient per
member (PPPM) budget impact of this treatment is 46-53 cents. Medical cost offsets
were estimated but were insignificant compared to total cost of treatment. US payers
rated PPPM output as the one of the most important relevant outputs of model.
CONCLUSIONS: This budget impact model shows that new treatments for rare
forms of cancer are likely to have minimal budget impact on payers. PPPM based
outputs are more relevant to payers, than per patient treatment costs. However, an
emerging concern is the total budget impact of all therapies indicated for ultra-
orphan disorders, which might be an important consideration for future models.
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BUDGET IMPACT ANALYSIS OF SWITCHING TO DIGITAL MAMMOGRAPHY IN A
BREAST CANCER POPULATION-BASED SCREENING PROGRAM
Arrospide A1, Comas M2, Mar J1, Sala M2, Hernandez C3, Roman R2, Castells X2
1Hospital Alto Deba, Mondragon, Spain, 2Hospital del Mar-IMIM, CIBER de Epidemiología y Salud
Pública (CIBERESP), Barcelona, Spain, 3Hospital del Mar-IMIM, Barcelona, Spain
OBJECTIVES:Digital mammography is costlier than screen film mammography but
presents benefits at the technological and logistic level. The aim of this study was
to analyze the budget impact and the health benefits of the introduction of digital
mammography in a population-based breast cancer screening program.
METHODS: A discrete-event simulation model was implemented including the
processes under a breast cancer screening program and the natural history of
breast cancer. The screening events included: invitation (biennial) of the target
population (women aged 50-69 years), participation, screening test, confirmatory
tests after a positive mammography result, cancer diagnosis and treatment. Nat-
ural history of breast cancer included the following health states: no cancer, pre-
clinical (non symptomatic) cancer, clinical (or symptomatic) cancer and death.
Digital and analogical mammography had the same sensitivity, but different spec-
ificities were applied according to type of mammography and also initial or suc-
cessive screening. Results were collected during a 20-year screening scenario.
RESULTS: A total of 90,575 women were screened under both techniques during
the simulated 20 years. This population resulted in more than 262,500 screening
mammograms. The recall rate was 5.9% under digital mammography and 6.4%
under analogical mammography, while the numbers of confirmatory tests needed
were 23,728 and 32,697, respectively. The cancer detection rate was 0.7% for both
techniques. Digital mammography saved 1.909.167 euros in additional tests, while
it was 1.026.807 euros more expensive in screening mammograms and presented
similar costs of treatments. CONCLUSIONS: Results suggest that, although popu-
lation-based breast cancer screening with digital mammography is costlier in
terms of screening mammographies, it saves money in terms of additional tests
needed. The health benefits are similar to those of conventional analogical mam-
mography, but it reduces the number of additional tests needed, which represent a
clear benefit to participating women.
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LONG-TERM FISCAL IMPLICATIONS OF MEPACT IN THE TREATMENT OF HIGH-
GRADE NON-METASTATIC OSTEOSARCOMA: A BUDGET IMPACT MODEL AND A
LIFETIME TAX PERSPECTIVE
Johal S1, Knight C2, Bell MJ3, Ralston S4
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Solutions, Manchester, UK, 4Takeda Global Research & Development Centre (Europe) Ltd,
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OBJECTIVES: The addition of MEPACT as an add-on treatment to adjuvant chemo-
therapy in the treatment of high-grade non-metastatic osteosarcoma after macro-
scopically complete surgical resection has been shown to significantly increase
overall survival of young patients. This study assessed the costs (drug and admin-
istration) and the long-term financial impact on the UK (UK) government of intro-
ducing MEPACT. METHODS: Based on the cost of MEPACT and using survival rates
derived from a clinical trial, we projected the net budgetary impact of MEPACT
compared to no MEPACT. Further, we modelled the net tax contribution to the state
of a surviving patient over a lifetime by subtracting direct government transfers
that are made to the individual (child benefit, education etc) from the individual’s
gross tax contribution based on average anticipated earnings. RESULTS: Using UK
incidence rates of osteosarcoma the model estimated approximately 54 newly di-
agnosed non-metastatic cases per year. Assuming that 38 doses of MEPACT (cal-
culated from trial data) are added to the treatment regimen of 50% of patients at a
cost of £91,189 , the expected 1-year cost would be UK £3,972k compared with
£1,450k had all patients been treated without MEPACT. Administration costs ac-
counted for 3% of total costs. The lifetime discounted value of net taxes from a 14
year old patient treated with MEPACT is £79,000. The breakeven age, defined as the
point at which the net tax contribution becomes greater than zero, is approxi-
mately 41 years. CONCLUSIONS: The additional budget impact due to MEPACT is
mainly due to the cost of the drug. From the tax calculations, we conclude that
investment in MEPACT does not negatively impact the long run fiscal budget of the
UK government. Conversely, by taking a broader government perspective over an
average lifetime, a surviving patient returns a positive net value to the State.
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BUDGET IMPACT ANALYSIS FOR CHRONIC MIELOID LEUKEMIA THERAPY IN
BULGARIA
Savova A1, Petrova G2
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University, Faculty of
Pharmacy, Sofia, Bulgaria
OBJECTIVES: To evaluate the budget impact of nilotinib for newly diagnosed pa-
tients with chronic myeloid leukemia (CML) for the health care system in Bulgaria.
METHODS: Current standard of therapy (imatinib) is compared with the newly
authorized for sale nilotinib and dasatinib used as a first line therapy. Cost of yearly
pharmacotherapy and adverse drug reactions management have been calculated
for 3 years for different proportions of newly diagnosed patients with CML in
chronic phase. The exchange rate is 1 BGN  0.51 EUR. RESULTS: Clinical studies
shows significant benefits from nilotinib but the question remains if it is worth the
cost of therapy. Calculation of the yearly pharmacotherapy cost per 100 patients
arranges the medicines in monetary value order as follows: 5,398,092 BGN for ima-
tinib, 6,564,681 BGN for nilotinib, and 8,365,872 BGN for dasatinib. Weighed cost by
the probability of appearing of the ADR is 733.26 BGN for imatinib, 509.75 for nilo-
tininb, and 1,010.29 BGN for dasatinib. The relative share of patients treated with
nilotinib in first line is 12% for the first year, 32% for the second, and 38% for the
third year. The introduction of nilotinib will change the budget for all patients with
CML to 6,895,316 in comparison with 6,725,246 BGN before the introduction, to
7,177,671 BGN in the second year, and to 7,262,378 BGN in the third year. Thus the
over all increase for the observed 3 years will be within 179,044 BGN.
CONCLUSIONS: The introduction of nilotinib as first line therapy for patients with
newly diagnosed CML will lead to relatively small increase in the health care bud-
get in Bulgaria compared to the clinical benefit in terms of achievement of deeper
response, improvement of overall survival and less disease progression.
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CAPECITABINE FOR THE TREATMENT OF BREAST CANCER IN PRIVATE HEALTH
SYSTEM IN BRAZIL: COST ANALYSIS BASED ON REAL WORLD DATA
Clark O1, Clark LGO1, Botrel TEA1, Rosa B2, Medina P1, Paladini L3, Fiol E2, Rodrigues N2,
Faleiros E1, Castro AP2, Fortes AF2
1Evidências, Campinas, Brazil, 2Evidências, Campinas, SP, Brazil, 3Evidências, São Paulo, São
Paulo, Brazil
OBJECTIVES: Capecitabine (C) is approved in Brazil for the treatment of breast
cancer (BC), 2nd or subsequent lines. In the private sector, it’s not often used, due
to the fact that health insurance plans (HI) do not offer coverage for oral (PO)
chemotherapy (CHEMO), only for intravenous (IV). Our aim was to determine if the
use of C could spare costs if adopted by HI. METHODS: We searched Evidencias
Database for BC patients eligible for the use of C, in the year of 2008. This database
has information from over 2 million of users of 14 HI. We identified the IV CHEMO
actually used and the costs paid. Then, based on the data of each individual patient
and in the length of use of CHEMO, we calculated the associated costs in a scenario
where C replaced the IV CHEMO used. Also, we performed some sensitivity analysis
based on different percentages of substitutions of IV by PO chemo. We considered
only the prices of drugs. RESULTS: We found 518 BC patients eligible for C use.
These patients received 3581 cycles of chemotherapy (Paclitaxel, Docetaxel, Gem-
citabine, Vinorelbine, Doxorubicin). The total cost for these treatments were US$ 5
364 000. If C replaced 100% of the IV CHEMO, the total cost would drop to
US$2,078,000, 62% smaller than the IV alternative. In a simulation, where 60% of the
patients would use the IV option and 40% would use C, the total cost would also be
smaller: US$4,050,000, 25% smaller than when IV route is used exclusively.
CONCLUSIONS: The adoption of C by HI in Brazil is cost-saving for BC patients.
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BUDGETARY IMPACT OF ADOPTION OF ERLOTINIB FOR LUNG CANCER IN THE
PRIVATE HEALTH INSURANCE MARKET IN BRAZIL: A REAL WORLD DATA
ANALYSIS
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